Evidence map›Paper›PMID 31932420›Full record

Trial reportProceedings of the National Academy of Sciences of the United States of America2020

Joe Zein, Benjamin Gaston, Peter Bazeley, Mark D DeBoer, Robert P Igo, Eugene R Bleecker, Deborah Meyers, Suzy Comhair, Nadzeya V Marozkina, Calvin Cotton and 22 more

2 registry-linked trialsOpen access · hybridAbstract readClinical Trial
In one paragraph

Trial report in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05623059 phase1 / phase2completednot on this mapstarted 2023, after this paper: background citation

Phase IIa Clinical Trial to Evaluate Pharmacokinetics and Safety of Slow Release DHEA

TypeinterventionalSponsorIndiana UniversityRan2023 to 2025Enrolled18ConditionsAsthma, GenotypeArmsSlow Release DHEA
NCT07179952 phase2not yet recruitingnot on this mapstarted 2027, after this paper: background citation

A Study to Evaluate Efficacy and Safety of Slow Release DHEA

TypeinterventionalSponsorIndiana UniversityRan2027 to 2028Enrolled30ConditionsAsthmaArmsSlow Release DHEA, Placebo
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Sex-biased Gene Expression Underlies Immune Dysfunction in Asthma.American journal of respiratory cell and molecular biology · 2025
    Pooled it
  2. Serendipity, steroids and science.The Journal of steroid biochemistry and molecular biology · 2026
    Review
  3. Hidden immune memory niches in inflammatory skin diseases.bioRxiv : the preprint server for biology · 2026
    Article
  4. Sex Differences in Asthma Pathogenesis.Immunological reviews · 2026
    Review
  5. Asthma Inception: Epidemiologic Risk Factors and Natural History Across the Life Course.American journal of respiratory and critical care medicine · 2024
    Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. The Influence of Sex Hormones and X Chromosome in Immune Responses.Current topics in microbiology and immunology · 2023
    Review
  11. Article
  12. Urinary total conjugated 3-bromotyrosine, asthma severity, and exacerbation risk.American journal of physiology. Lung cellular and molecular physiology · 2022
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Sex and gender in asthma.European respiratory review : an official journal of the European Respiratory Society · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 17 institutions in 2 countries.

Joe ZeinLerner Research Institute and the Respiratory Institute, Cleveland Clinic, Cleveland, OH 44195.
Benjamin GastonHerman Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202.
Peter BazeleyLerner Research Institute and the Respiratory Institute, Cleveland Clinic, Cleveland, OH 44195.
Mark D DeBoerDepartment of Pediatrics, University of Virginia, Charlottesville, VA 22904.
Robert P IgoDepartment of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH 44106.
Eugene R BleeckerDepartment of Medicine, University of Arizona Health Sciences, Tucson, AZ 85721.
Deborah MeyersDepartment of Medicine, University of Arizona Health Sciences, Tucson, AZ 85721.
Suzy ComhairLerner Research Institute and the Respiratory Institute, Cleveland Clinic, Cleveland, OH 44195.
Nadzeya V MarozkinaDepartment of Pediatrics, Rainbow Babies and Children's Hospital, and Case Western Reserve University, Cleveland, OH 44106.ORCID 0000-0002-1692-8634
Calvin CottonDepartment of Pediatrics, Rainbow Babies and Children's Hospital, and Case Western Reserve University, Cleveland, OH 44106.
Mona PatelLerner Research Institute and the Respiratory Institute, Cleveland Clinic, Cleveland, OH 44195.
Mohammad AlyamaniLerner Research Institute and the Respiratory Institute, Cleveland Clinic, Cleveland, OH 44195.
Weiling XuLerner Research Institute and the Respiratory Institute, Cleveland Clinic, Cleveland, OH 44195.
William W BusseDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53706.
William J CalhounDepartment of Medicine, University of Texas Medical Branch, TX 77555.
Victor OrtegaInternal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27587.
Gregory A HawkinsInternal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27587.
Mario CastroDepartment of Medicine, University of Kansas School of Medicine, Kansas City, KS 66160.
Kian Fan ChungThe National Heart & Lung Institute, Imperial College London, London SW7 2AZ, United Kingdom.ORCID 0000-0001-7101-1426
John V FahyDepartment of Pediatrics, San Francisco School of Medicine, University of California, San Francisco, CA 94143.
Anne M FitzpatrickDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322.
Elliot IsraelDepartment of Medicine, Harvard Medical School, Boston, MA 02115.
Nizar N JarjourDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53706.
Bruce LevyDepartment of Medicine, Harvard Medical School, Boston, MA 02115.
David T MaugerCenter for Biostatistics and Epidemiology, Pennsylvania State University School of Medicine, Hershey, PA 16802.
Wendy C MooreInternal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27587.
Patricia NoelSevere Asthma Research Program (SARP), National Heart, Lung, and Blood Institute, NIH, Bethesda, MD 20892.
Stephen P PetersInternal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27587.
W Gerald TeagueDepartment of Pediatrics, University of Virginia, Charlottesville, VA 22904.
Sally E WenzelUniversity of Pittsburgh Asthma Institute, University of Pittsburgh Medical Center-University of Pittsburgh School of Medicine, Pittsburgh, PA 15261.
Serpil C ErzurumLerner Research Institute and the Respiratory Institute, Cleveland Clinic, Cleveland, OH 44195.
Nima SharifiLerner Research Institute and the Respiratory Institute, Cleveland Clinic, Cleveland, OH 44195; sharifn@ccf.org.ORCID 0000-0003-1281-3474
Cleveland Clinic Lerner College of Medicine · USWake Forest University · USHarvard University · USRainbow Babies & Children's Hospital · USUniversity of Arizona · USUniversity of Virginia · USUniversity of Wisconsin–Madison · USCase Western Reserve University · USEmory University · USImperial College London · GBIndiana University School of MedicineNational Heart Lung and Blood Institute · USPennsylvania State University · USThe University of Texas Medical Branch at Galveston · USUniversity of California, San Francisco · USUniversity of Kansas · USUniversity of Pittsburgh Medical Center · US

Funding

Targeting pathological hyaluronan matricesP01HL103453 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI ERZURUM, SERPIL C. · 2011 to 2020
$26.8M
Role of miRNAs in Th2-Driven inflammation in AsthmaP01HL107202 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FAHY, JOHN V · 2012 to 2023
$23.3M
Tissue Processing and Cell Culture COreP01HL081064 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI ERZURUM, SERPIL C. · 2006 to 2019
$17.8M
Project 3 - Personalized cystic fibrosis treatment strategies with synergistic therapies Identified in vitro.P01HL128192 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI GASTON, BENJAMIN · 2016 to 2020
$12.2M
S-nitrosothiol signaling in pulmonary epithelial cellsP01HL101871 · NHLBI · UNIVERSITY OF VIRGINIA · PI GASTON, BENJAMIN, LEWIS, STEPHEN JOHN · 2011 to 2015
$8.7M
Elucidating a novel molecular biomarker for castration-resistant prostate cancerR01CA172382 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Nima Sharifi · 2012 to 2026
$5.2M
Redox Determinants of Severe AsthmaR01HL069170 · NHLBI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI ERZURUM, SERPIL C. · 2001 to 2010
$5.1M
Airway redox biochemistry as a deteriminant of asthma phenotype during adolescen*U10HL109250 · NHLBI · UNIVERSITY OF VIRGINIA · PI ERZURUM, SERPIL C., GASTON, BENJAMIN · 2011 to 2016
$4.2M
Compensatory steroidogenesis mechanisms in castration-resistant prostate cancerR01CA190289 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI SHARIFI, NIMA · 2015 to 2019
$2.1M
Aberrant tumor metabolism that enables AR antagonist-resistant prostate cancerR01CA236780 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SHARIFI, NIMA · 2020 to 2024
$1.8M
Gender-based precision care for asthmaK08HL133381 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI ZEIN, JOE · 2017 to 2021
$836k
NCI NIH HHS R01 CA172382NCI NIH HHS R01 CA190289NCI NIH HHS R01 CA236780NHLBI NIH HHS K08 HL133381NHLBI NIH HHS P01 HL081064NHLBI NIH HHS P01 HL101871NHLBI NIH HHS P01 HL103453NHLBI NIH HHS P01 HL107202NHLBI NIH HHS P01 HL128192NHLBI NIH HHS R01 HL069170NHLBI NIH HHS U10 HL109250
6 · The paper itself

Abstract

Asthma resistance to glucocorticoid treatment is a major health problem with unclear etiology. Glucocorticoids inhibit adrenal androgen production. However, androgens have potential benefits in asthma.

Indexed as

AdultAgedAllelesAndrogensAsthmaCohort StudiesDrug ResistanceFemaleGenotypeGlucocorticoidsHumansMaleMiddle AgedMultienzyme ComplexesProgesterone ReductaseSteroid Isomerases3 beta-hydroxysteroid oxidoreductase-delta(5) 3-ketosteroid isomeraseAndrogensGlucocorticoidsMultienzyme ComplexesProgesterone ReductaseSteroid IsomerasesandrogensglucocorticoidsHSD3B1inflammationsteroids

Identifiers

PMID31932420
PMCPMC6995013
OpenAlexW2999602894

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.